ACADIA Pharmaceuticals Inc.
NASDAQ:ACADBiotechnology
-$0.13 today
- Market cap
- $3.04B
- Beta
- 0.83
- P/E (TTM)
- 9.7
- EPS (TTM)
- $2.20
Volume 1.45M
Average 1.66M
Income Statement
Follow revenue through to earnings.
Revenue
$1.07B
FY 2025 · Annual
+11.9% YoYOperating Income
$104.81M
FY 2025 · Annual
-54.6% YoYNet Income
$391.00M
FY 2025 · Annual
+72.7% YoYIncome Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 484.15M | 517.24M | 726.44M | 957.8M | 1.07B |
| Cost of Revenue | 19.14M | 10.17M | 45.73M | 81.84M | 89M |
| Gross Profit | 465M | 507.07M | 680.71M | 875.96M | 982.51M |
| Gross Margin | 96.0% | 98.0% | 93.7% | 91.5% | 91.7% |
| Research & Development | 239.42M | 361.58M | 351.62M | 303.25M | 328.8M |
| Selling, General & Admin | 396.03M | 369.09M | 402.47M | 488.43M | 548.89M |
| Operating Expenses | 635.44M | 730.67M | 754.09M | 645.16M | 877.7M |
| Depreciation & Amortization | 3.34M | 2.03M | 5.55M | 15.88M | 11.76M |
| EBITDA | (164.18M) | (211.42M) | (45.48M) | 100.16M | 150.66M |
| EBITDA Margin | -33.9% | -40.9% | -6.3% | 10.5% | 14.1% |
| Operating Income | (170.44M) | (223.6M) | (73.38M) | 230.79M | 104.81M |
| Operating Margin | -35.2% | -43.2% | -10.1% | 24.1% | 9.8% |
| Interest Income | 591K | 6.61M | 17.23M | 25.46M | 31.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.92M | 10.15M | 22.34M | 27.28M | 34.09M |
| Income Before Tax | (167.52M) | (213.44M) | (51.04M) | 258.08M | 138.9M |
| Pre-Tax Margin | -34.6% | -41.3% | -7.0% | 26.9% | 13.0% |
| Income Tax Expense | 351K | 2.53M | 10.25M | 31.62M | (252.1M) |
| Net Income | (167.87M) | (215.98M) | (61.29M) | 226.45M | 391M |
| Net Margin | -34.7% | -41.8% | -8.4% | 23.6% | 36.5% |
| EPS (Basic) | (1.05) | (1.34) | (0.37) | 1.37 | 2.32 |
| EPS (Diluted) | (1.05) | (1.34) | (0.37) | 1.36 | 2.29 |
| 160.49M | 161.68M | 163.82M | 165.72M | 169.34M | |
| 160.49M | 161.68M | 163.82M | 166.36M | 171.36M |
ACAD Earnings Waterfall · TTM
NASDAQ:ACAD · Revenue to Net Income
Key Ratios
Analysis
$1.2B of revenue converted into $362.2M of net income for the selected period. Gross margin is 68.1% and net margin is 30.9%, showing how much revenue survives after costs and taxes. EPS is $2.11, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
Market cap
$9.17B
Axsome Therapeutics, Inc.
NASDAQ:AXSM
Market cap
$7.45B
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Market cap
$1.39B
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Market cap
$1.25B
Alto Neuroscience, Inc.
NYSE:ANRO
Market cap
$1.18B
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
Market cap
$348.58M
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Market cap
$308.98M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Market cap
$241.27M
Anavex Life Sciences Corp.
NASDAQ:AVXL
Market cap
$86.53M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
Market cap
$80.59M
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 8-K | Current report | Oct 23, 2026 |
How much revenue does ACAD generate?
ACADIA Pharmaceuticals Inc. (ACAD) reported $1.07B of revenue in fiscal 2025.
Is ACAD profitable?
ACADIA Pharmaceuticals Inc. (ACAD) reported $391.00M of net income, with a net margin of 36.5%.
Continue the stock analysis
Jump to another research area for this company.